Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.

Pharmaceutical

Azura Ophthalmics

Marc Gleeson

Helga Mikkelsen

Guy Katsav

Patty Delaney

Omer Rafaeli

Ashwin Agarwal

Hila Barash

Yair Alster

Shimon Nahum

Charles Bosworth

Abby Aharonov

The Leadership Team at Azura Ophthalmics is responsible for steering the strategic direction of the company, ensuring the effective development and commercialization of innovative treatments for Meibomian gland dysfunction. Comprising key executives such as the CEO, CFO, CMO, CTO, and R&D officers, this team collaborates to align financial, medical, and technological objectives, fostering a culture of innovation while navigating regulatory landscapes and optimizing resource allocation for maximum impact in the ophthalmic field.

Leadership Team

Advisory Team

Research and Development Team

Leadership Team

About

Team members

Other teams at Azura Ophthalmics

Advisory Team

Research and Development Team